Cargando…

Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough

Gefapixant is a P2X3‐receptor antagonist being developed for treatment of refractory or unexplained chronic cough. Four phase 1 studies were conducted in healthy participants that bridged the early‐phase gefapixant formulation (F01) to the phase 3 (F04A) and intended commercial (F04B) formulations....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Pranav, Hussain, Azher, Ford, Anthony P., Smith, Steven, Nussbaum, Jesse C., Stoch, Aubrey, Iwamoto, Marian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540877/ https://www.ncbi.nlm.nih.gov/pubmed/35510785 http://dx.doi.org/10.1002/cpdd.1105

Ejemplares similares

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
por: Nussbaum, Jesse C., et al.
Publicado: (2022)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant
por: Chawla, Akshita, et al.
Publicado: (2023)

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Efficacy of gefapixant, a P2X(3) antagonist, for lung cancer-related cough: a case report
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
por: Martinez, Fernando J., et al.
Publicado: (2021)

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
por: Cui, Wen-Wen, et al.
Publicado: (2022)

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023)

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2021)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
por: Khalilieh, Sauzanne, et al.
Publicado: (2020)

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants
por: Gillespie, Gillian, et al.
Publicado: (2021)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Randomised trial of the P2X(3) receptor antagonist sivopixant for refractory chronic cough
por: Niimi, Akio, et al.
Publicado: (2022)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
por: Ankrom, Wendy, et al.
Publicado: (2018)

Clinical validation of efficacy and safety of herbal cough formulation “Honitus syrup” for symptomatic relief of acute non-productive cough and throat irritation
por: Gupta, Arun, et al.
Publicado: (2016)

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
por: Friedrich, Christian, et al.
Publicado: (2023)

In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization
por: Ford, Anthony P.
Publicado: (2011)

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
por: Rudd, Deanne Jackson, et al.
Publicado: (2021)

A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
por: Ankrom, Wendy, et al.
Publicado: (2021)

Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency
por: Matthews, Randolph P., et al.
Publicado: (2022)

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants
por: Iwamoto, Marian, et al.
Publicado: (2023)

TRPV1 antagonists attenuate antigen-provoked cough in ovalbumin sensitized guinea pigs
por: McLeod, Robbie L, et al.
Publicado: (2006)

Recent advances in antiemetics: new formulations of 5HT(3)-receptor antagonists
por: Gilmore, James, et al.
Publicado: (2018)

Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine
por: O’Brien, Fiona, et al.
Publicado: (2019)

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

Cough and fever in an immigrant adolescent with abnormal chest X-ray
por: Giles, Nicole, et al.
Publicado: (2016)

Cough hypersensitivity and chronic cough
por: Chung, Kian Fan, et al.
Publicado: (2022)

Retinoid X Receptor Antagonists
por: Watanabe, Masaki, et al.
Publicado: (2018)

COUGHING UP A LUNG
por: ABO-ZED, ABDELRHMAN, et al.
Publicado: (2021)

Cough projectile during emergence
por: Gupta, Deepak
Publicado: (2020)

Cough variant asthma and atopic cough
por: Magni, Chiara, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_097eoa9q6t20qlao4t6j3mkm7h